Initial results found that among 1060 participants in 30 countries, the pembrolizumab plus CCRT group conferred better PFS at 24 months than the placebo plus CCRT group (68% vs 57%; hazard ratio ...
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...
After hours: February 28 at 5:29:10 p.m. EST ...
Subaru-PFS/drp_stella_data’s past year of commit activity ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback